Biomedical Engineering Reference
In-Depth Information
229. Lien EA et al (1987) Determination of tamoxifen and four metabolites in serum by
low-dispersion liquid chromatography. Clin Chem 33:1608-1614
230. Lee KH et al (2003) Quantification of tamoxifen and three metabolites in plasma by high-
performance liquid chromatography with fluorescence detection: application to a clinical
trial. J Chromatogr B Analyt Technol Biomed Life Sci 791:245-253
231. Zhu YB et al (2008) Optimizing high-performance liquid chromatography method with
fluorescence detection for quantification of tamoxifen and two metabolites in human plasma:
application to a clinical study. J Pharm Biomed Anal 46:349-355
232. Esteve-Romero J et al (2010) Tamoxifen monitoring studies in breast cancer patients by
micellar liquid chromatography. Anal Bioanal Chem 397:1557-1561
233. Carter SJ et al (2001) Biomonitoring of urinary tamoxifen and its metabolites from breast
cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrom-
etry. Electrophoresis 22:2730-2736
234. Mihailescu R et al (2000) Identification of tamoxifen and metabolites in human male urine by
GC/MS. Biomed Chromatogr 14:180-183
235. Zweigenbaum J et al (2000) Bioanalytical high-throughput selected reaction monitoring-LC/
MS determination of selected estrogen receptor modulators in human plasma: 2000 samples/
day. Anal Chem 72:2446-2454
236. Sheth HR et al (2003) Aging may be associated with concentrations of tamoxifen and its
metabolites in breast cancer patients. J Womens Health 12:799-808
237. Tucker AN et al (2005) Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associ-
ated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in
breast cancer patients. Cancer Lett 217:61-72
238. Gjerde J et al (2005) Identification and quantification of tamoxifen and four metabolites in
serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1082:6-14
239. Williams LD et al (2006) Quantification of tamoxifen and metabolites and soy isoflavones in
human plasma using liquid chromatography with electrospray ionization tandem mass spec-
trometry. J AOAC Int 89:1168-1173
240. Wu AH et al (2007) Tamoxifen, soy, and lifestyle factors in Asian American women with
breast cancer. J Clin Oncol 25:3024-3030
241. Furlanut M et al (2007) Tamoxifen and its main metabolites serum and tissue concentrations
in breast cancer women. Ther Drug Monit 29:349-352
242. Teunissen SF et al (2009) Development and validation of a quantitative assay for the analysis
of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and gly-
citein in human serum using liquid chromatography coupled with tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci 877:2519-2529
243. Ahmad A et al (2010) Orally administered endoxifen is a new therapeutic agent for breast
cancer. Breast Cancer Res Treat 122:579-584
244. Ahmad A et al (2010) Endoxifen, a new cornerstone of breast cancer therapy: demonstration
of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol
Ther 88:814-817
245. Jaremko M et al (2010) Tamoxifen metabolite isomer separation and quantification by liquid
chromatography-tandem mass spectrometry. Anal Chem 82:10186-10193
246. Teunissen SF et al (2011) Development and validation of a quantitative assay for the determi-
nation of tamoxifen and its five main phase I metabolites in human serum using liquid chro-
matography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol
Biomed Life Sci 879:1677-1685
247. Binkhorst L et al (2011) Quantification of tamoxifen and three of its phase-I metabolites in
human plasma by liquid chromatography/triple-quadrupole mass spectrometry. J Pharm
Biomed Anal 56:1016-1023
248. Poon GK et al (1993) Analysis of phase I and phase II metabolites of tamoxifen in breast
cancer patients. Drug Metab Dispos 21:1119-1124
249. Poon GK et al (1995) Identification of tamoxifen metabolites in human Hep G2 cell line,
human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab
Dispos 23:377-382
Search WWH ::




Custom Search